Mitochondrial Resilience in Glaucoma: Targeting NAD+ Metabolism and Oxidative Stress in Retinal Ganglion Cell Degeneration with Nicotinamide Riboside and Berberine: Preliminary Clinical Evidence
Federico Visalli, Francesco Cappellani, Giuseppe Gagliano, Alfonso Spinello, Alessandro Avitabile, Ludovica Cannizzaro, Matteo Capobianco, Caterina Gagliano, Marco Zeppieri

TL;DR
This paper explores how nicotinamide riboside and berberine may protect retinal cells in glaucoma by improving mitochondrial health and reducing oxidative stress.
Contribution
The study provides preliminary clinical evidence for the combined use of nicotinamide riboside and berberine in glaucoma management.
Findings
Combined supplementation of nicotinamide riboside and berberine showed functional stabilization of the visual field in glaucoma patients.
The treatment preserved retinal nerve fiber layer structure over six months, aligning with mitochondrial protective mechanisms.
The AMPK–SIRT–NRF2 pathway may be engaged to enhance mitochondrial resilience in retinal ganglion cells.
Abstract
Background: Glaucoma is a chronic neurodegenerative disorder characterized by the selective vulnerability of retinal ganglion cells (RGCs), in which mitochondrial dysfunction, redox imbalance, and impaired bioenergetic signaling play central pathogenetic roles. Mitochondrial homeostasis in RGCs critically depends on maintaining intracellular NAD+ pools, which support oxidative phosphorylation, sirtuin-mediated deacetylation, and antioxidant gene expression. Nicotinamide riboside (NR), a potent NAD+ precursor, and berberine (BBR), an AMPK activator derived from Berberis aristata, have recently emerged as synergistic modulators of mitochondrial metabolism and oxidative stress resistance. Methods: This study retrospectively assessed clinical outcomes associated with combined nutraceutical supplementation of nicotinamide riboside (NR) and berberine (BBR) in patients with primary open-angle…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsBerberine and alkaloids research · PARP inhibition in cancer therapy · Sirtuins and Resveratrol in Medicine
